ADAM10 and central nervous system cancer: Notably, this NLGN3-induced proliferation was attenuated by first pre-treating glioma cells with ADAM10 inhibitor, even in the presence of NLGN3 (Extended Data Fig. 5b), consistent with the hypothesized role for ADAM10-mediated CSPG4 cleavage in the NLGN3-CSPG4-PIEZO1 mechanism.